Introduction {#sec1-1}
============

Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic hyperglycemia resulting from an absolute deficiency of insulin secretion or a reduction in the biologic effectiveness of insulin (or both).\[[@ref1]\] It is associated with acute complications such as ketoacidosis, hyperosmolar state, and hypoglycemia, as well as long-term complications affecting the eyes, kidneys, feet, brain, heart, nerves, and blood vessels. DM is broadly classified into Type 1 DM (T1DM) which occurs as a result of absolute insulin deficiency and T2DM; the predominant form of diabetes (\>90%) is characterized by relative insulin deficiency or resistance.\[[@ref1][@ref2]\]

Type 1A diabetes is caused by autoimmune destruction of the pancreatic β-cells, thereby leading to absolute insulin deficiency and subsequent dependency on insulin in most patients.\[[@ref3]\] The pancreatic autoantibodies implicated in the autoimmune process include glutamic acid decarboxylase antibody (GAD-Ab), islet cell cytoplasmic antibody (ICA), and antibodies to the protein tyrosine phosphatases Islet antibody (IA2 or IA2-β). The GAD-Ab, which is more sensitive and higher concentration in adult population, is used to diagnose Type 1A diabetes (T1A) among adult patients.\[[@ref2][@ref4][@ref5]\]

Latent autoimmune diabetes in adults (LADA) is a form of TIA diabetes that occurs late and can be mistaken as a T2DM. It is characterized by age usually \>30 years, lean body mass, insulin independence within the first 6 months of diagnosis, positive GAD-Ab, and low serum C-peptide level.\[[@ref6][@ref7][@ref8][@ref9]\] LADA shared both features of T1DM: presence of autoantibody (GAD-Ab), decreased body mass index (BMI), and less C-peptide and T2DM characteristics of late-onset and insulin resistance.\[[@ref7][@ref8][@ref10]\] It has been found that the LADA subset of patients has similar or even higher genetic predisposition to develop nonimmune diabetes as compared to those GAD-Ab^−^ diabetes.\[[@ref11]\] Because of this unique combination of features, this form of diabetes is sometimes referred to as Type 1.5 diabetes.

There is a wide difference in prevalence of LADA among various population groups across the globe. Recently, Arikan *et al*.,\[[@ref12]\] in a study among Turkish population, comparing long-term complications of diabetes among GAD-Ab^+^ and GAD-Ab^−^ patients, documented a prevalence of 31% of LADA while Bosi *et al*.,\[[@ref13]\] in a population-based study in Italy, found as low as 2.8% prevalence of LADA. In a similar previous study in Southern Nigeria, Ipadeola *et al*.\[[@ref14]\] and Adeleye *et al*.\[[@ref15]\] reported a prevalence of LADA among T2DM patients to be 11.9% and 14.0%, respectively.

In Ghana, Agyei-Frempong *et al*.\[[@ref16]\] in a clinic-based study reported a prevalence of 11.7% and also found less metabolic syndrome indices among the GAD-Ab^+^ than in GAD-Ab^−^ patients. Among Caucasians, Tuomi *et al*.\[[@ref5]\] reported a prevalence of LADA among Finnish population to be 9.2% while Hwangbo *et al*.\[[@ref17]\] in Korea found 4.3%. In both studies, they found decreased secretory capacity of the β-cells, less BMI and hypertension, decreased triglycerides (TGs), and poor glycemic control in the LADA group. The differences in the prevalence of LADA among populations may not be unrelated to the characteristics of the study populations, genetic predisposition, type of assay used, and the adopted criteria for diagnosis.

It is evident from most of the previous studies, from different populations, race and regions of the globe, that LADA patients exhibit rapid deterioration of β-cell function as manifested in the poor glycemic control and subsequent insulin dependency. This needs to be identified early and proper classification of diabetic subjects so as to reduce and or delay the consequences of long-term complications of diabetes among LADA group of patients.

In this study, we measured GAD-Ab among noninsulin-requiring T2DM patients with the aim to estimate the prevalence of LADA in Northern Nigeria and also to compare the clinical characteristics between GAD-Ab^+^ and that of GAD-Ab^−^ subgroups of diabetics.

Methods {#sec1-2}
=======

The study was a descriptive and cross-sectional; it involved a study population drawn from T2DM patients attending the diabetes clinic of a tertiary health institution in Northern Nigeria. The study was approved by the Ethics Committee of the institution and lasted 1 year between December 2007 and January 2008.

Subjects {#sec2-1}
--------

Two-hundred consecutive T2DM patients, who consented, were recruited from the diabetes clinic based on some selection criteria.

Inclusion criteria include noninsulin-requiring T2DM patient of at least 6 months duration and age of 30 or more years. Patients on insulin, pregnant women, presence of systemic diseases or organ failure, and use of drugs, especially steroids, were excluded from the study.

Clinical procedure {#sec2-2}
------------------

The consecutive patients attending the diabetes clinic who satisfied the inclusion criteria were administered questionnaires on the first contact. The demographic data including age, sex, age at onset, duration of diabetes, history of hypertension or diabetes, and family history of diabetes were recorded.

All subjects had clinical examination. The weight was measured to the nearest 0.5 kg and height in meters using stadiometer. BMI was calculated from weight and height.\[[@ref18]\] Waist circumference (WC) was measured to the nearest centimeter at the midpoint between the lowermost rib and the anterior superior iliac spine while hip circumference was measured at the level of greater trochanter. The patients were then asked to come for a next visit (2 weeks) after fasting for 8--12 h.

Sample collection {#sec2-3}
-----------------

On the second visit, 10 ml of fasting venous blood was taken from all the subjects. The samples were immediately separated, and the plasma stored at −22°C. All the patients had their plasma samples analyzed for glucose, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, glycated hemoglobin (HbA1c), C-peptide, and anti-GAD-Ab.

Glutamic acid decarboxylase antibody {#sec2-4}
------------------------------------

The GAD-Ab estimation was done using Kronus Kronus anti glutamic acid decarboxylase kit (ELISA), Boise, USA. It depends on the ability of GAD autoantibodies to act divalently and forms a bridge between GAD coated on ELISA plate wells and liquid phase GAD biotin. The GAD-biotin bound is then quantitated by addition of streptavidin-peroxidase and a chlorogenic substrate tetramethylbenzidine with reading of final absorbance at wavelengths (450 and 405 nm) to obtain maximum measuring range (4--200 units/ml of WHO reference preparation). Less than 5 units/ml is considered positive.\[[@ref19]\]

Fasting plasma glucose {#sec2-5}
----------------------

Plasma glucose was estimated using glucose oxidase method.

Glycated hemoglobin {#sec2-6}
-------------------

The principle involved is micro-column method as a direct way of estimating HbA1c. After preparing the hemolysate where the labile fraction is eliminated, HbA1c is specifically eluted after washing away; the HbA1a+ b fraction is quantified by direct photometric reading at 415 nm. HbA1c Quantitative kit (Agappe Diagnostic Ltd., India) was used.\[[@ref20]\]

Lipids {#sec2-7}
------

TC was estimated through an enzymatic method using the generated color to show the amount of cholesterol in the sample. HDL-C was estimated after the precipitation of LDL-C and very LDL-C by polyanions in the presence of magnesium ion. TGs in the sample were measured by the same spectrophotometry while LDL-C was estimated using fried Wald\'s formula: LDL-C = TC -- HDL-C+ TGs/2.2.

C-Peptide {#sec2-8}
---------

C-peptide estimation was done using Kronus ELISA kit (Boise, USA); reading was done at 450 nm with value \<1.0 µ/ml as considered low.

Statistical analysis {#sec2-9}
--------------------

The data were analyzed using Statistical package for social sciences version 20 (SPSS Inc, Chicago, IL, USA), and it was presented as mean ± standard deviation (SD). Student\'s *t*-test was used to compare means while Chi-square was used to compare categorical/nominal groups. A binary logistic regression was used to determine the relationship between dependent and independent variables. A two-tailed *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Characteristics of the study population {#sec2-10}
---------------------------------------

The study population comprised 200 noninsulin-requiring Type 2 diabetic subjects who were attending the diabetic clinic in Ahmadu Bello University Teaching Hospital, Zaria. The mean (SD) age of the subjects was 53 (9.2) years, range (34--75), and comprising 80 (40%) males and 120 (60%) females \[[Table 1](#T1){ref-type="table"}\].

###### 

The clinical characteristics of the study population

  Variable   Mean (SD)
  ---------- -------------
  Age        53 (9.21)
  AAD        46 (9.37)
  DOD        7 (5.46)
  BMI        26.8 (5.21)
  WC         91.9 (11.7)
  WHR        0.99 (0.05)
  SBP        142 (23.8)
  DBP        89 (11.1)
  FBG        8.2 (3.21)
  PPG        12.2 (3.53)
  HbA1c      7.45 (1.85)
  TC         5.0 (0.94)
  LDL-C      3.8 (0.96)
  TG         1.1 (0.34)
  HDL-C      0.72 (0.23)

AAD=Age at diagnosis, DOD=Duration of diabetes, BMI=Body mass index, WC=Waist circumference, WHR=Waist hip ratio, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, FBG=Fasting blood glucose, PPG=Postprandial glucose, HbA1c=Glycated hemoglobin, TC=Total cholesterol, LDL-C=Low-density lipoprotein cholesterol, HDL-C=High-density lipoprotein cholesterol, TG=Triglyceride, SD=Standard deviation

Prevalence of glutamic acid decarboxylase autoantibody {#sec2-11}
------------------------------------------------------

Of the 200 patients studied, 21 (10.5%) were found positive for GAD-Ab comprising 15 (71%) males and 6 (29%) females. Chi-square = 4.2, *P* \< 0.05 \[[Figure 1](#F1){ref-type="fig"}\].

![The distribution of glutamic acid decarboxylase antibody by sex](AAM-15-163-g001){#F1}

[Figure 2](#F2){ref-type="fig"} shows that 48% of GAD-Ab was found in the age group of 40--49, 28% in 60--69, 10% each was found in the group 30--39 and 50--59 while above 70 years has 4.7%.

![The distribution of glutamic acid decarboxylase antibody positive by age group](AAM-15-163-g002){#F2}

Clinical characteristics of glutamic acid decarboxylase antibodies positive and negative diabetic patients compared {#sec2-12}
-------------------------------------------------------------------------------------------------------------------

The mean age (SD) of patients with GAD-Ab^+^ (*n* = 21) and GAD-Ab^−^ (*n* = 179) was 52 (11) and 53 (9), *P* \> 0.05, respectively. There was also no significant difference at the age of onset and duration of diabetes among the two groups. Both the two groups of the diabetic patients were noninsulin- requiring and also were not place on any of the anti-lipid drugs.

The mean BMI of GAD-Ab^+^, 22.1 (12.4), was significantly lower than that of GAD-Ab^−^, 27.3 (4.9), *P* = 0.002 \[[Table 2](#T2){ref-type="table"}\]. The majority of the GAD-Ab^+^ subjects have either normal BMI (57%) or underweight (24%) \[[Figure 3](#F3){ref-type="fig"}\]. The mean WC of GAD-Ab^+^ subjects was significantly lower than that of GAD-Ab^−^ subjects, 80.1 (12.4) and 93.2 (10.9), respectively, *P* = 0.001. There was no difference in waist-hip ratio between the two groups. Both the mean systolic and diastolic blood pressures were lower in GAD-Ab^+^ subjects although of no statistical significance.

###### 

Comparison of clinical characteristics between glutamic acid decarboxylase antibodies positive and negative

  Variable    Mean (SD)       *P*            
  ----------- --------------- -------------- ---------
  Age         52.0 (11.02)    53.0 (9.06)    0.937
  AAD         46.7 (10.23)    45.9 (9.32)    0.810
  DOD         6.1 (3.75)      7.1 (5.63)     0.582
  BMI         22.1 (5.09)     27.3 (4.98)    0.002\*
  WC          80.1 (12.38)    93.2 (10.92)   0.001\*
  WHR         0.99 (0.29)     1.00 (0.05)    0.865
  SBP         139.6 (15.96)   142.5 (24.6)   0.712
  DBP         86.0 (8.430)    89.5 (11.3)    0.347
  FBG         8.7 (2.19)      8.1 (3.31)     0.602
  PPG         12.7 (3.11)     12.1 (3.58)    0.633
  TC          5.0 (0.78)      5.0 (0.96)     0.993
  LDL-C       3.97 (0.79)     3.8 (0.98)     0.650
  HDL-C       0.69 (0.17)     0.72 (0.24)    0.669
  TG          0.87 (0.42)     1.07 (0.33)    0.069
  HbA1c       8.3 (1.4)       7.0 (2.1)      0.003\*
  C-peptide   0.84 (0.05)     1.72 (0.43)    0.002\*

AAD=Age at diagnosis, DOD=Duration of diabetes, BMI=Body mass index, WC=Waist circumference, WHR=Waist hip ratio, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, FBG=Fasting blood glucose, PPG=Postprandial glucose, HbA1c=Glycated hemoglobin, TC=Total cholesterol, LDL-C=Low-density lipoprotein cholesterol, HDL-C=High-density lipoprotein cholesterol, TG=Triglyceride, GAD=Glutamic acid decarboxylase, SD=Standard deviation

![Percentage of body mass index classes among glutamic acid decarboxylase antibody positive subjects](AAM-15-163-g003){#F3}

The glucose control among the two groups was poorer in GAD-Ab^+^ subject than in the GAD-Ab^−^ with mean HbA1c of 8.3 (1.4) and 7.0 (2.1), respectively, *P* = 0.003. There was no significant difference in mean fasting blood glucose and 2-hrpp between the two groups.

The mean TG is lower in GAD-Ab^+^, 0.87 (0.42), than in GAD-Ab^−^, 1.07 (0.33), *P* \> 0.05. There were no differences in the mean values of TC, LDL-C, and HDL-C between the two groups.

The mean C-peptide level in GAD-Ab^+^ is significantly lower than in GAD-Ab^−^ patients, 0.84 (0.05)/1.72 (0.43), *P* \< 0.05.

Binary logistic regression analysis was performed to ascertain the effects of age, sex, BMI, WC, HbA1c, and TG to predict GAD-Ab^+^ among the patients. In this study, it was found that the WC and male sex were predictors of GAD-Ab^+^ among T2DM subjects. The logistic regression model was 48 Nagelkerke R2, and 96% predicted correctly that GAD-Ab occurs from the independent variables contribution of sex and WC, *P* \< 0.05.

Discussion {#sec1-4}
==========

The 200 noninsulin-requiring Type 2 diabetic patients who were studied have age range of 34--75 years and have more females than males (120 vs. 80 or a ratio of 3:2). This pattern of diabetes distribution between gender groups is in keeping with earlier work as reported by Bakari and Onyemelukwe\[[@ref21]\] and more recently by Olamoyegun *et al*.\[[@ref22]\] both in Nigeria.

LADA is a form of autoimmune diabetes that occur late, or with advancing age, and noninsulin- requiring at onset.\[[@ref9]\] It is characterized by progressive and slowly β-cell destruction by an autoimmune mechanism involving attack by GAD, ICA, or IA-2 autoantibodies. The GAD-Ab is said to be more sensitive than IA-2 and higher titer in adults than in children.\[[@ref4][@ref5]\] This explained the reason of using GAD-Ab, as against other autoantibodies, to detect LADA subgroup of diabetes among T2DM subjects.

The prevalence of LADA among T2DM subjects in this study was found to be 10.5% (21/2000). In a previous study of GAD-Ab among T2DM patients in Southwest Nigeria, a prevalence rate of 11.9% was documented.\[[@ref14]\] Adeleye *et al*.\[[@ref15]\] in a similar survey also, in Southwest Nigeria, reported a prevalence rate of 14.0%. The observed prevalence rates between these previous studies and the present one may be explained by the differences in the age group of those found with GAD-Ab^+^ and the selection of noninsulin-requiring subjects at the outset of this study.

In similar studies in Ghana, West Africa, Agyei-Frempong *et al*.\[[@ref16]\] found a rate of 11.7% while in Kenya, East Africa, a lower rate of 5.7% was documented by Otieno *et al*.\[[@ref23]\] Elsewhere in Korea, Hwangbo *et al*.\[[@ref17]\] reported a prevalence rate of 4.3% while Brahmkshatriya *et al*.\[[@ref9]\] from India found a rate of 5.0%. The prevalence of GAD-Ab among T2DM across populations is greatly varied which ranges from as low as 2.8% to more than 31%. The observed differences in prevalence may be related to sampling technique, patient demography, genetic predisposition, and type of assay used. [Table 3](#T3){ref-type="table"} depicts the prevalence rates of GAD-Ab^+^ among different populations.

###### 

Prevalence of glutamic acid decarboxylase antibody positive (late autoimmune diabetes in adult) in type two diabetes subjects among different population groups

  Author                                Country                    Study type         Subjects (n)   Prevalence
  ------------------------------------- -------------------------- ------------------ -------------- ------------
  Current study                         Northern Nigeria           Clinic-based       200            10.5
  Adeleye *et al*.^\[[@ref15]\]^        Southwest Nigeria          Clinic-based       160            11.9
  Ipadeola *et al*.^\[[@ref14]\]^       Southwest Nigeria          ✓                  235            14.0
  Agyei *et al*.^\[[@ref16]\]^          Ghana                      ✓                  120            11.7
  Otieno *et al*.^\[[@ref23]\]^         Kenya                      ✓                  124            5.7
  Hwangbo *et al*.^\[[@ref17]\]^        Korea                      ✓                  462            4.3
  Tuomi *et al*.^\[[@ref5]\]^           Finland                    Population-based   1122           9.3
  Bosil *et al*.^\[[@ref13]\]^          Italy                      ✓                  2076           2.8
  Zinman *et al*.^\[[@ref31]\]^         North America and Europe   ✓                  4134           4.2
  Arikan *et al*.^\[[@ref12]\]^         Turkey                     Clinic-based       54             31
  Brahmkshatriya*et al*.^\[[@ref9]\]^   India                      ✓                  500            5.0

In this study, males were found to have GAD-Ab^+^ more than their female counterparts; 71% (15/21):29% (6/21), *χ*^2^ = 4.2, *P* \< 0.05 \[[Figure 1](#F1){ref-type="fig"}\]. A similar finding was reported by Brahmkshatriya *et al*.\[[@ref9]\] among Indian population; however, previous studies in Southwest Nigeria reported no gender bias of GAD-Ab^+^ among T2DM patients.\[[@ref14][@ref15]\] The observed differences of GAD-Ab among gender between the current study (Northern Nigeria) and the previous (Southern Nigeria) may be due to population demographics and/or genetic predisposition.\[[@ref24]\]

The most common age group found to have GAD-Ab^+^, in this study, was 40--49 years 48% \[[Figure 2](#F2){ref-type="fig"}\]. This finding supported previous studies that showed advancing age, just like T2DM, is a risk factor for the development of LADA.\[[@ref5][@ref15][@ref25]\] This further buttress the fact that the pathogenesis of LADA has both the autoimmune and insulin resistance components, advancing age is also known to be a risk factor for insulin resistance, which has been shown to play a role in LADA.\[[@ref26]\]

In this study, we found the mean BMI and WC of patients with GAD-Ab^+^ to be significantly lower than that of the patients with GAD-Ab^−^ (22.1 ± 5.0, 80.1 ± 12.4 vs. 27.3 ± 4.9, 93.2 ± 10.9), *P* \< 0.05. In a similar study in Southern Nigeria, Ipadeola *et al*.\[[@ref14]\] reported that LADA patients were leaner and had poor glycemic control than T2DM patients. Agyei-Frempong *et al*.\[[@ref16]\] in a study of autoimmune diabetes among Ghanaians documented lower central obesity among LADA than in T2DM subjects. These findings supported the fact that LADA patient shared similar characteristics with T1DM of been lean, less metabolic indices, and insulin dependency.

Other indices of metabolic syndrome including hypertension, HDL-C, and TG tended to be lower in GAD-Ab^+^ subjects though of no significance value. Similar studies among Europeans showed significantly lower metabolic syndrome parameters among LADA patients.\[[@ref8][@ref27][@ref28]\] Arikan *et al*.\[[@ref12]\] in a study of microvascular complications among LADA patients in Turkey found lower BMI, C-peptide, and lesser age at onset of diabetes in this subset of patients.

In China national survey on GAD-Ab^+^ among T2DM, Zhou *et al*.\[[@ref7]\] documented that LADA patients were significantly leaner and had decreased C-peptide level and less metabolic syndrome than GAD-Ab^−^ T2DM patients. The study further showed that patients with high GAD-Ab^+^ are phenotypically different from those with low GAD-Ab^+^. This showed that GAD-Ab^+^ could be used for LADA stratification and accurate therapeutic choice.

It was also reported among Caucasians that GAD-Ab^+^ level correlates well with the β-cell function as exhibited by the level of C-peptide.\[[@ref8][@ref29][@ref30][@ref31]\] In this study, we found poorer glycemic control among GAD-Ab^+^ than in GAD-Ab^−^ subjects as demonstrated in the level of HbA1c. We also observed lower C-peptide level in GAD-Ab^+^ than in those with GAD-Ab^−^ patients which suggest decreased secretory capacity of the β-cells following the autoimmune process in GAD-Ab^+^ patients.

Insulin resistance as the major T2DM pathologic mechanism was also found to play a role in GAD-Ab^+^ or LADA patients.\[[@ref10]\] Hence, it is rational to expect that LADA subgroup shares the same characteristics with both T1DM and T2DM, and therapeutic approaches must take this into cognizance.

Conclusion {#sec1-5}
==========

We concluded that the prevalence of LADA among recently diagnosed noninsulin-requiring T2DM patients in Northern Nigeria was 10.5%. The patients were lean, more common in males and age group 40--49 years, exhibited less metabolic syndrome, and decreased β-cell secretory capacity as demonstrated by low C-peptide level.
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